Top Markets
Coin of the day
TetraLogic Pharmaceuticals Corporation TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation

TLOG
Rang in aandelen #42528
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage... TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
Aandeelprijs
$0.00004
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$979.00
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-60.00%
Land
US
Handel TetraLogic Pharmaceuticals Corporation (TLOG)

Categorie

EPS voor TetraLogic Pharmaceuticals Corporation (TLOG)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van TetraLogic Pharmaceuticals Corporation is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van TetraLogic Pharmaceuticals Corporation van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten